An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g
This study has been completed.
First Posted: April 26, 2005
Last Update Posted: June 21, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Information provided by (Responsible Party):
This is a Phase IIIb, multicenter, open-label, extension study available to subjects who successfully complete Study Q2143g and have not participated in Study Q2195g. Subjects should be registered via the IVRS (Interactive Voice Response System) within 48 hours prior to their baseline visit. All subjects in this study will be treated with Xolair for 24 weeks. Subjects in the New Treatment Group may require additional visits for study drug injections (as frequently as every 2 weeks). Data collection during these additional visits will be limited to the assessment of adverse events. The study will evaluate all serious and nonserious adverse events, laboratory assessments, data on asthma exacerbations, and concomitant medication usage.
Drug: Xolair (omalizumab)
||Masking: None (Open Label)
Primary Purpose: Treatment
||Open-Label Extension Study II of Xolair (Omalizumab) in Moderate to Severe, Persistent Asthma Subjects Who Completed Study Q2143g (ALTO)
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:
||Child, Adult, Senior
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- Successful completion of the 24-week study period in Study Q2143g
- Signed informed consent (in the case of a minor, consent must be given by the child's parent or legally authorized representative)
- For subjects who have never received Xolair, a serum IgE level >=30 IU/mL and <=1300 IU/mL and have a body weight >=20 kg and <=150 kg
- Females of childbearing potential must, in the opinion of the investigator, be using an effective method of contraception to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.
- Thrombocytopenia as evidenced by a platelet count of <100,000/uL
- Pregnant or breastfeeding
- Significant systemic disease (e.g., infection, hematologic, renal, hepatic, coronary heart disease or other cardiovascular diseases, endocrine or gastrointestinal disease) within the previous 3 months
- History of neoplasia
- Any systemic condition requiring regular administration of an immunoglobulin
- Known hypersensitivity to any ingredients of Xolair, including excipients (sucrose, histidine, polysorbate 20)
- History of noncompliance with medical regimens
- Current participation in a study using an investigational new drug other than Xolair
- Participation in Study Q2195g
No Contacts or Locations Provided
History of Changes
|Other Study ID Numbers:
||April 26, 2005
||April 26, 2005
|Last Update Posted:
||June 21, 2013
Keywords provided by Genentech, Inc.:
Moderate Persistent Asthma
Severe Persistent Asthma
Additional relevant MeSH terms:
Respiratory Tract Diseases
Lung Diseases, Obstructive
Immune System Diseases
Respiratory System Agents